Safety and tolerability of sildenafil citrate was assessed in a population subset of 60 Singaporean men with erectile dysfunction taken from the Asian Sildenafil Efficacy and Safety Study (ASSESS-I), a double-blind, placebo-controlled, flexibledose study. The men, from two centres, with ≥ 6 months' history of erectile dysfunction, were randomized to two treatment arms for 12 weeks. One group (30 patients) received sildenafil (initial dose 50 mg taken 1 h before sexual activity for the first 2 weeks, increased to 100 mg or decreased to 25 mg, according to efficacy and/or tolerability). The remaining 30 patients received a matching placebo. Incidence and type of adverse effects were evaluated at 2, 4, 8 and 12 weeks. Nine patients (30.0%) on sildenafil (33.1% in the full ASSESS-I study) and one patient (3.3%) on placebo (22.8% in the full ASSESS-I study) experienced treatment-related adverse events, the most frequent being headache in the sildenafil group (reported by five patients [16.7%]; 11.0% in the full ASSESS-I study). Flushing, visual disturbance, dizziness, insomnia, myalgia and back pain each occurred in one patient in the sildenafil group (3.3%); in the placebo group, one patient (3.3%) had headache. Importantly, the incidence of cardiovascular and respiratory system adverse events were relatively less than in the full ASSESS-I population (cardiovascular 3.3% in the present study versus 10.2% in the full ASSESS-I population; respiratory 3.3% versus 5.5%). All adverse events were transient and mild, and did not lead to treatment withdrawal. There was no effect on sitting blood pressure, heart rate or standard laboratory parameters; more importantly, there was no incidence of myocardial infarction, stroke or priapism. These results should reassure Singaporean patients and their physicians of the safety of sildenafil for erectile dysfunction.
Introduction
Men with erectile dysfunction (ED) are often reluctant to seek medical advice, due to embarrassment, myths about the condition arising from cultural beliefs, lack of awareness about the availability of effective therapies and uncertainty about their safety. The exact prevalence of ED in Singapore has not been established, but it is well known that ED increases with age and is more common in men with diabetes mellitus and vascular disease. 1, 2 These situations highlight the need for an effective agent that is simple to use, does not interfere with the spontaneity of the sexual relationship and has minimal adverse events.
Many clinical trials have demonstrated the efficacy of oral sildenafil therapy for men with ED of varied aetiology, 3 -6 and sildenafil has become the focus of intense attention from patients and the medical community. Some patients have been reluctant to accept sildenafil treatment due to its associated effects, however, which prompted us to evaluate its safety and tolerability in Singaporean men. A recent overview of safety data from clinical studies in western men 7 showed sildenafil to be well tolerated, with a low discontinuation rate due to adverse events.
The ASSESS-I (Asian Sildenafil Efficacy and Safety Study) trial was an eight-centre, randomized, double-blind, placebo-controlled evaluation of sildenafil, given to Asian men with ED, in flexible doses over a 12-week period. 8 In addition, the pre-marketing experience was expected to provide a baseline for post-marketing clinical management. Although cumulative clinical safety and efficacy data are reported for Asian patients in the ASSESS-I study, 8 the findings of the present study focus on the sub-population of Singaporean men within ASSESS-I. We chose to analyse adverse events in this sub-population that may affect the safety profile of sildenafil, because of differences in the racial composition of men recruited to the Singaporean, Malaysian and Filipino arms. In Singapore, 71% of the population is of Chinese origin, whereas in Malaysia, the Malay population (58%) predominates, and differences in efficacy with sildenafil have been reported elsewhere between these populations. 9 The present paper addresses the comprehensive account of the clinical safety of sildenafil specifically in Singaporean men with ED.
Patients and methods
The Singaporean arm of the ASSESS-I study was conducted between July 1997 and March 1998. Sixty men with ED, who had been unable to attain and/or maintain penile erection sufficient for satisfactory sexual intercourse 10 for a minimum of 6 months' duration, who were in stable, heterosexual relationships, were enrolled. Patients with the following were excluded: genital anatomical abnormalities or spinal-cord injuries; coexisting sexual disorders; abnormally raised prolactin or lowered free testosterone levels; major psychiatric disorders; substance abuse; major haematological, renal or hepatic abnormalities; stroke, myocardial infarction or other significant cardiovascular disease within the previous 6 months; hypotension; poorly controlled diabetes mellitus; retinitis pigmentosa; therapy with androgens, trazodone, nitrates, nitric oxide (NO) donor compounds; prescription of any drug known to be causally associated with ED. Informed consent was obtained from each patient. The study was conducted in accordance with the International Conference on Harmonisation Tripartite Guideline for Good Clinical Practice and the ethical committee regulations of each centre.
During the initial 4-week run-in period, medical/drug history, physical examination, 12-lead electrocardiogram (ECG), sitting 
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blood pressure (BP), heart rate, baseline haematological and blood chemistry tests were undertaken. Subjects were then randomly assigned to two matched groups, each containing 30 patients, to receive either sildenafil or placebo for a 12-week period. The initial dose was 50 mg (or a matching placebo) taken approximately 1 h before anticipated sexual activity, not more than once daily. After 2 weeks, the dosage was either increased to 100 mg or reduced to 25 mg, depending on individual efficacy or tolerability, at the investigator's discretion. The details of sexual activity and medication taken were recorded in event logs; patients were advised not to consume > 2 units of alcohol before sexual activity.
Patients were evaluated at 2, 4, 8 and 12 weeks for adverse events. All observed or reported events were recorded, irrespective of the relationship to the study medication. At each visit, sitting BP and heart rate were measured; and at the end of the 12-week treatment period physical examination, 12-lead ECG, and standard haematological and blood chemistry tests were repeated.
Results
Age, body weight and aetiology of ED of all patients are shown in Table 1 . No patient withdrew due to severe adverse events in either group. No patient required dose reduction or temporary discontinuation of treatment. Efficacy data (i.e. the influence of treatment regimen on erectile activity and sexual function) for patients enrolled in ASSESS-I are reported elsewhere. 8
ADVERSE EVENTS
All-cause adverse events (regardless of whether or not there was a suspected relationship to the study medication) and treatment-related adverse events are compared in Table 2 for Singaporean men versus the full ASSESS-I population. Nine men (30.0%) on sildenafil experienced treatment-related adverse events, compared with one patient (3.3%) on placebo. Headache was the most common adverse event, reported by five patients on sildenafil (16.7%) compared with one patient (3.3%) on placebo. Flushing, due to vasodilatation, occurred in one patient (3.3%) on sildenafil and no patient on placebo. In the sildenafil group, visual disturbances, back pain and myalgia each occurred in one patient (3.3%). In general, the incidence of cardiovascular and respiratory system adverse events was reduced in Singaporean patients (cardiovascular adverse events 3.3% versus 10.2%; respiratory system adverse events 3.3% versus 5.5%) compared with the findings of the ASSESS-I report, 8 which also included men from Malaysia and the Philippines. There were some differences in incidence of adverse events reported in the The only adverse event reported in the Singaporean patients on placebo was headache, which occurred in one patient; conversely, in the ASSESS-I study, 8 4.7%, 3.9% and 3.9% cardiovascular, respiratory-and nervous system-mediated adverse events were recorded.
Adverse events were mostly mild in Singaporean men receiving sildenafil, with a moderately severe event (headache) reported in one patient. There was no influence on cardiovascular parameters (sitting BP and heart rate) and no evidence of myocardial infarction, stroke or priapism
LABORATORY TEST FINDINGS
No difference in baseline and post-treatment laboratory parameters was reported between the sildenafil and placebo groups in the Singaporean men, although laboratory anomalies had been noted in patients from Malaysia and the Philippines. 8 No patient was required to discontinue treatment due to abnormal findings. The only abnormality occurring in patients in the sildenafil group, who each had normal baseline values, was a low platelet count (defined as < 75 × 10 9 /l) in one patient. This patient had no clinical symptoms and the low count resolved spontaneously.
Discussion
The efficacy of sildenafil for the treatment of various types of ED has been reported in many studies, 3 -6 but the safety profile of this therapy has become an issue of particular interest for patients and their primary care givers.
The physiological process of penile erection begins with a release of NO from nonadrenergic-noncholinergic nerves and endothelial cells of the corpus cavernosum. This process activates guanyl cyclase, which synthesizes cyclic guanosine monophosphate (cGMP), a potent 'second messenger' responsible for smooth-muscle relaxation. 11, 12 Relaxation of smooth muscle in the corpus cavernosum and penile arteries increases blood flow into the lacunar spaces of the corpus cavernosum and compresses the draining venules, leading to erection. 12 Sildenafil inhibits cGMP-specific phosphodiesterase type 5, the predominant form of the enzyme in the corpus cavernosum, thereby reducing the degradation of cGMP. This improves the erectile response to sexual stimuli. 13 Studies of the pharmacokinetic and pharmacodynamic profile of sildenafil have demonstrated its suitability for use on an 'as required' basis. Peak plasma concentrations are attained in 1 h following oral administration and the duration of its effect is short, due to its 4 h residual half-life. Sildenafil is known for peripheral vasodilatory activity, but the drug has no clinically significant effects on BP or heart rate. 13 The initial dose for most patients is 50 mg, taken 1 h before anticipated sexual activity, that can be either increased to 100 mg or decreased to 25 mg, depending on efficacy and tolerability in the individual.
Our study in Singaporean men has demonstrated the flexible-dose regimen of sildenafil to be well tolerated, with a low incidence of adverse events that were mild; no patient discontinued sildenafil treatment. Headache, the most common treatmentrelated adverse event, and flushing (vasodilatation) are both consistent with the drug's activity on phosphodiesterase type 5 and the NO/cGMP pathway. Visual disturbance, myalgia and back pain were seen in three patients (one symptom in each) but there was no incidence of myocardial infarction, stroke or priapism during the 12-week trial.
The present findings are comparable to a clinical safety overview of 28 phase II and phase III studies with sildenafil. 7 This PHC Lim, FC Ng, CWS Cheng et al.
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overview was conducted in western populations and included 18 double-blind, placebo-controlled evaluations and 10 longterm, open-label extensions, with pooled safety data from more than 3700 patients and 1631 years of drug exposure. 7 In placebocontrolled studies, headache was the most common adverse event reported by sildenafiltreated patients (16%), 3 -5 followed by flushing (10%), dyspepsia (7%), nasal congestion (4%) and abnormal vision (3%); these events were mild (62%) or moderate (31%) in nature. The rate of discontinuation due to adverse events was 2.5% for sildenafil compared with 2.3% for placebo. 7 A 2% discontinuation rate due to adverse events was also seen in long-term, open-label studies. 7 The incidence of adverse events increased with higher dosages in various fixed-dose studies of sildenafil, 7 but discontinuation rates were only slightly higher with 100 mg doses (1.2%) than with doses of 25 mg or 50 mg (0.4 -0.6%). 7 The low incidence of adverse cardiovascular events, and the absence of short-or long-term increases in occurrence of serious cardiovascular events that we found in Singaporean patients on sildenafil, are similar to findings reported in the overview analysis of phase II/III studies. 7 Similarly, there were no significant changes in BP, heart rate or ECG parameters. The incidence of adverse cardiovascular events other than flushing in the 18 placebo-controlled studies was 3.0% with sildenafil, and 3.5% with placebo; 7 most of these events were mild or moderate in severity. Indeed, there were no serious sildenafil-related adverse events. 7 The issue of tolerability of sildenafil treatment in men on anti-hypertensive therapy is of particular interest because hypertensive men often report ED. Hypertension was reported by 20% of subjects receiving sildenafil in our study and 33% of patients on sildenafil in the overview analysis. 7 Findings from our study and the overview analysis have established the tolerability of sildenafil in men receiving anti-hypertensive treatment to be similar to normal healthy men. A recent review of 18 double-blind, placebocontrolled studies showed no difference in the incidence of treatment-related adverse events (e.g. hypotension, dizziness and syncope) between sildenafil-treated patients with and without anti-hypertensive medication. 14 Other studies in the overview analysis have addressed the safety issue of co-administration of sildenafil with organic nitrates; 7 this co-administration has been found to be potentially hazardous, leading to clinically significant decreases in BP. Consequently, sildenafil is absolutely contraindicated in men receiving nitrates or NO donor agents. 7, 15 The incidence of transient and mild adverse events with sildenafil treatment was low in Singaporean patients, and no discontinuation of treatment was observed, similar to the findings in studies conducted in western populations. The most common adverse events were headache and flushing, which are attributable to the modest peripheral vasodilator activity of sildenafil. Indeed, finding no occurrence of myocardial infarction or stroke was most reassuring; our results also show the concomitant administration of sildenafil and anti-hypertensive medication to be safe and tolerable.
